🇺🇸 FDA
Patent

US 11041008

Heterodimers of IL-15 and IL-15R alpha to increase thymic output and to treat lymphopenia

granted A61KA61K38/00A61K38/1793

Quick answer

US patent 11041008 (Heterodimers of IL-15 and IL-15R alpha to increase thymic output and to treat lymphopenia) held by The Government of the United States of America as represented by the Secretary of the Deptartment of Health and Human Services expires Mon Jun 17 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Government of the United States of America as represented by the Secretary of the Deptartment of Health and Human Services
Grant date
Tue Jun 22 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 17 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
12
CPC classes
A61K, A61K38/00, A61K38/1793, A61K38/2086, A61K45/06